Merck, Inc.
🇺🇸United States
MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT02181803
Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT02180165
A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)
Phase 3
Withdrawn
- Conditions
- Herpes Zoster
- Interventions
- Biological: V212 Lot 1Biological: V212 Lot 2Biological: V212 Lot 3
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT02180295
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT02180061
Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02174159
Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT02161510
Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)
Phase 4
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT02155335
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Phase 2
Completed
- Conditions
- Melanoma
- Interventions
- Biological: Pegylated Interferon Alfa-2b
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT02155322
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 305
- Registration Number
- NCT02142738
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Phase 3
Completed
- Conditions
- Prevention of CMV Infection or Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 570
- Registration Number
- NCT02137772